4-氧代-哌嗪-1-基-丁酸 | 72547-43-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-氧代-哌嗪-1-基-丁酸
• 英文名称: 4-oxo-4-piperazin-1-yl-butyric acid
• 英文别名: 4-Oxo-4-piperazin-4-ium-1-ylbutanoate
• CAS: 72547-43-4
• 化学式: C₈H₁₄N₂O₃
• mdl: MFCD03042137
• 分子量: 186.211
• InChiKey: XBPFUNIGMQMISX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 4-氧代-哌嗪-1-基-丁酸 在 sodium hydroxide 作用下， 生成 4-(3-羧基丙酰基)-哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  Calcium-promoted hydrolysis of N-acylureas allows mild release of peptides anchored with the Dpr(Phoc) linker to hydrophilic resins

  摘要：

  Calcium chloride is an efficient additive for promoting the release of short peptide models anchored with Dpr(Phoc) linker to hydrophilic solid-phase synthesis supports. It was shown to induce a moderate to marked (especially for C-terminal proline peptides) increase in the rate of alkaline hydrolytic cleavage, without epimerization at the C-terminal residue, while substantially reducing the hydroxide ion concentration. Base-promoted side-reactions are therefore expected to be slowed down. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00973-8
• 作为产物：
  描述：

  哌嗪 、 丁二酸酐 在 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 4-氧代-哌嗪-1-基-丁酸
  参考文献：
  名称：

  Calcium-promoted hydrolysis of N-acylureas allows mild release of peptides anchored with the Dpr(Phoc) linker to hydrophilic resins

  摘要：

  Calcium chloride is an efficient additive for promoting the release of short peptide models anchored with Dpr(Phoc) linker to hydrophilic solid-phase synthesis supports. It was shown to induce a moderate to marked (especially for C-terminal proline peptides) increase in the rate of alkaline hydrolytic cleavage, without epimerization at the C-terminal residue, while substantially reducing the hydroxide ion concentration. Base-promoted side-reactions are therefore expected to be slowed down. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00973-8

文献信息

• Indole derivatives with vascular damaging activity
  申请人：——

  公开号：US20030216356A1

  公开（公告）日：2003-11-20

  The invention provides a compound of Formula (I) wherein: R 1 and R 2 are independently selected from hydrogen, halogen, —CN, a hydrocarbyl group or a group of Formula (II); wherein W is aryl or a heterocyclic group, R 4 is independently select from hydrogen, halogen, —OH, amino, alkanoylamino, —OPO 3 H 2 , or a hydrocarbyl group, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified or two R 4 groups together form an optionally substituted cyclic or heterocyclic group; X is selected from $M(y) S+—, +—O—+, —+S(O)+—, —+S(O 2 )+— and —+NH—; p is an integer from 0 to 4; and q is an integer from 1 to 4; R 3 and R 10 are independently selected from hydrogen, lower alkyl or a group of Formula (IV): wherein Y is selected from +NH+—, —$M(Y)O$M(Y)— or a bond; Z is selected from +NH+—, —+O&ngr;—, —+C(O)+— or a bond; r is an integer from 0 to 4; t is an integer from 0 to 1; R 6 is hydrogen, a hydrocarbyl group or a group of Formula (V): wherein n is an integer of from 1 to 6, and; R 7 and R 8 are independently selected from hydrogen or a hydrocarbyl group; and R 11 is hydrogen or lower alkyl; or a salt or solvate thereof; provided that: I) when R 1 is an unsubstituted phenylthio group (Ph—S—), R 2 is H, R 10 is H and R 11 is H then R 3 is neither H nor —C(O)—O—CH 2 CH 3 ; and ii) R 1 , R 2 and R 3 are not all hydrogen. Such compounds are predicted to cause the selective destruction of tumour vasculature. They may therefore be used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis. 1

  该发明提供了一个化合物，其化学式为（I），其中：R1和R2分别选自氢、卤素、—CN、烃基团或化学式（II）的基团；其中W为芳基或杂环基团，R4独立选择自氢、卤素、—OH、氨基、烷酰胺基、—OPO3H2或烃基团，其中氨基团可选择性地被氨基酸残基取代，羟基可选择性酯化，或两个R4基团共同形成一个可选择性取代的环状或杂环基团；X选自$M(y)S+—、+—O—+、—+S(O)+—、—+S(O2)+—和—+NH—；p为0至4之间的整数；q为1至4之间的整数；R3和R10独立选择自氢、较低烷基或化学式（IV）的基团：其中Y选自+NH+—、—$M(Y)O$M(Y)—或键；Z选自+NH+—、—+O&ngr;—、—+C(O)+—或键；r为0至4之间的整数；t为0或1之间的整数；R6为氢、烃基团或化学式（V）的基团：其中n为1至6之间的整数；R7和R8独立选择自氢或烃基团；R11为氢或较低烷基；或其盐或溶剂化合物；但要求：I）当R1为未取代的苯硫基团（Ph—S—）时，R2为H，R10为H且R11为H，则R3既不是H也不是—C(O)—O—CH2CH3；和II）R1、R2和R3不全为氢。预测这类化合物可能导致肿瘤血管的选择性破坏。因此，它们可以用于抑制和/或逆转和/或缓解血管生成及/或与血管生成相关的任何疾病状态的症状。
• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Bolin David Robert

  公开号：US20100145047A1

  公开（公告）日：2010-06-10

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
  申请人：Kovach John S.

  公开号：US20090036309A1

  公开（公告）日：2009-02-05

  This invention provides compounds having the structure which may be used for the treatment of tumors.

  这项发明提供了具有该结构的化合物，可用于肿瘤治疗。
• Chemical compounds
  申请人：Arnould Jean-Claude

  公开号：US20050159474A1

  公开（公告）日：2005-07-21

  The invention relates to the use of a compound of Formula (I), for the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis: wherein: X, p, q, R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the description. The invention also related to use of compounds of Formula (I) as medicaments and also to novel compounds of Formula (I). The invention further provides pharmaceutical compositions of compounds of Formula (I) and processes for the synthesis of compounds of Formula (I).

  本发明涉及使用式（I）的化合物制造药物，以抑制和/或逆转和/或缓解血管生成及/或与血管生成相关的任何疾病状态的症状：其中：X，p，q，R1，R2，R3，R4和R5如说明书中定义的那样。本发明还涉及使用式（I）的化合物作为药物，以及式（I）的新化合物。本发明还提供了式（I）的化合物的制药组合物和合成式（I）的化合物的过程。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。